|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EGFR |
Gene summary for EGFR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EGFR | Gene ID | 1956 |
| Gene name | epidermal growth factor receptor | |
| Gene Alias | ERBB | |
| Cytomap | 7p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q504U8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1956 | EGFR | CA_HPV_1 | Human | Cervix | CC | 2.14e-07 | -2.95e-01 | 0.0264 |
| 1956 | EGFR | CA_HPV_3 | Human | Cervix | CC | 1.15e-12 | 3.49e-01 | 0.0414 |
| 1956 | EGFR | CCI_1 | Human | Cervix | CC | 1.13e-21 | 2.02e+00 | 0.528 |
| 1956 | EGFR | CCI_2 | Human | Cervix | CC | 4.65e-04 | 1.18e+00 | 0.5249 |
| 1956 | EGFR | CCI_3 | Human | Cervix | CC | 8.86e-25 | 1.67e+00 | 0.516 |
| 1956 | EGFR | Tumor | Human | Cervix | CC | 1.95e-06 | 3.01e-01 | 0.1241 |
| 1956 | EGFR | sample3 | Human | Cervix | CC | 1.78e-19 | 4.03e-01 | 0.1387 |
| 1956 | EGFR | T3 | Human | Cervix | CC | 1.92e-12 | 3.21e-01 | 0.1389 |
| 1956 | EGFR | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.41e-08 | -4.24e-01 | 0.0155 |
| 1956 | EGFR | HTA11_347_2000001011 | Human | Colorectum | AD | 3.34e-10 | 6.12e-01 | -0.1954 |
| 1956 | EGFR | HTA11_411_2000001011 | Human | Colorectum | SER | 5.78e-04 | 7.22e-01 | -0.2602 |
| 1956 | EGFR | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.02e-13 | -4.52e-01 | 0.294 |
| 1956 | EGFR | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.95e-07 | -4.41e-01 | 0.3859 |
| 1956 | EGFR | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.21e-27 | -6.79e-01 | 0.3005 |
| 1956 | EGFR | F007 | Human | Colorectum | FAP | 3.80e-04 | -3.45e-01 | 0.1176 |
| 1956 | EGFR | A015-C-203 | Human | Colorectum | FAP | 7.86e-35 | -4.60e-01 | -0.1294 |
| 1956 | EGFR | A015-C-204 | Human | Colorectum | FAP | 1.06e-05 | -3.33e-01 | -0.0228 |
| 1956 | EGFR | A014-C-040 | Human | Colorectum | FAP | 1.30e-03 | -3.14e-01 | -0.1184 |
| 1956 | EGFR | A002-C-201 | Human | Colorectum | FAP | 1.67e-18 | -5.41e-01 | 0.0324 |
| 1956 | EGFR | A001-C-119 | Human | Colorectum | FAP | 1.90e-10 | -6.44e-01 | -0.1557 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
| GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
| GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
| GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
| GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
| GO:005212610 | Cervix | CC | movement in host environment | 52/2311 | 175/18723 | 7.03e-10 | 8.76e-08 | 52 |
| GO:004440910 | Cervix | CC | entry into host | 47/2311 | 151/18723 | 8.45e-10 | 1.03e-07 | 47 |
| GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
| GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
| GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:004671810 | Cervix | CC | viral entry into host cell | 44/2311 | 144/18723 | 5.47e-09 | 5.03e-07 | 44 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
| GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
| hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
| hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
| hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
| hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
| hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
| hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
| hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa051207 | Cervix | CC | Epithelial cell signaling in Helicobacter pylori infection | 24/1267 | 70/8465 | 4.35e-05 | 3.09e-04 | 1.83e-04 | 24 |
| hsa0521010 | Cervix | CC | Colorectal cancer | 27/1267 | 86/8465 | 8.60e-05 | 5.57e-04 | 3.30e-04 | 27 |
| hsa052197 | Cervix | CC | Bladder cancer | 16/1267 | 41/8465 | 1.45e-04 | 9.05e-04 | 5.35e-04 | 16 |
| hsa052148 | Cervix | CC | Glioma | 24/1267 | 75/8465 | 1.51e-04 | 9.20e-04 | 5.44e-04 | 24 |
| hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
| hsa052128 | Cervix | CC | Pancreatic cancer | 24/1267 | 76/8465 | 1.89e-04 | 1.11e-03 | 6.55e-04 | 24 |
| hsa015223 | Cervix | CC | Endocrine resistance | 28/1267 | 98/8465 | 3.82e-04 | 1.87e-03 | 1.11e-03 | 28 |
| hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
| hsa0491212 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| AREG | EGFR | AREG_EGFR | EGF | Breast | ADJ |
| HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | ADJ |
| AREG | EGFR | AREG_EGFR | EGF | Breast | DCIS |
| AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Breast | DCIS |
| HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | DCIS |
| HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Breast | DCIS |
| EREG | EGFR | EREG_EGFR | EGF | Breast | DCIS |
| EREG | EGFR_ERBB2 | EREG_EGFR_ERBB2 | EGF | Breast | DCIS |
| AREG | EGFR | AREG_EGFR | EGF | Breast | Healthy |
| HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | Healthy |
| EREG | EGFR | EREG_EGFR | EGF | Breast | Healthy |
| AREG | EGFR | AREG_EGFR | EGF | Breast | Precancer |
| HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | Precancer |
| EREG | EGFR | EREG_EGFR | EGF | Breast | Precancer |
| AREG | EGFR | AREG_EGFR | EGF | Cervix | ADJ |
| HBEGF | EGFR | HBEGF_EGFR | EGF | Cervix | ADJ |
| AREG | EGFR | AREG_EGFR | EGF | Cervix | CC |
| AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Cervix | CC |
| HBEGF | EGFR | HBEGF_EGFR | EGF | Cervix | CC |
| HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Cervix | CC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EGFR | SNV | Missense_Mutation | novel | c.941N>G | p.Asp314Gly | p.D314G | P00533 | protein_coding | tolerated(0.26) | benign(0.031) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EGFR | SNV | Missense_Mutation | rs532655845 | c.439G>A | p.Ala147Thr | p.A147T | P00533 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| EGFR | SNV | Missense_Mutation | c.3151N>A | p.Asp1051Asn | p.D1051N | P00533 | protein_coding | tolerated(0.6) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| EGFR | SNV | Missense_Mutation | c.1577G>C | p.Cys526Ser | p.C526S | P00533 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EGFR | SNV | Missense_Mutation | c.340G>A | p.Glu114Lys | p.E114K | P00533 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| EGFR | SNV | Missense_Mutation | rs201717672 | c.3602N>T | p.Ala1201Val | p.A1201V | P00533 | protein_coding | deleterious(0.01) | benign(0.284) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EGFR | SNV | Missense_Mutation | rs138847501 | c.769G>A | p.Glu257Lys | p.E257K | P00533 | protein_coding | deleterious(0.01) | benign(0.206) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| EGFR | SNV | Missense_Mutation | c.2540N>A | p.Thr847Lys | p.T847K | P00533 | protein_coding | deleterious(0) | possibly_damaging(0.555) | TCGA-C8-A1HG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EGFR | SNV | Missense_Mutation | c.340G>A | p.Glu114Lys | p.E114K | P00533 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| EGFR | SNV | Missense_Mutation | rs121913465 | c.2303N>T | p.Ser768Ile | p.S768I | P00533 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | AMG 595 | |||
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 249565586 | POZIOTINIB | |
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | CHEMBL1201827 | PANITUMUMAB | |
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 385612228 | ||
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | gefitinib | GEFITINIB | 18681783,17375033,22370314,14990633,16467544,16377102,17317677,14990632,18784101,17020982,19473722,21921847,16912157,19589612,20573926,16258541,19692680,22581822,17192902,16203769,16257339,17429313,18000659,17085664,18003960,19381876,17473659,15897572,22215752,26490356,23022519,21900837,20038723,16865253,11255078,17285735,15118073,20022809,16115929,19339720,18316547,19201048,22760226,16204011,16956694,17597605,12648464,21233402,18992959,22237259,22594511 | |
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | Pyrrolo[2,3-d]pyrimidine derivative 24 | |||
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | INC280 | CAPMATINIB | 28783719 | |
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 363894206 | ALLITINIB | |
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | CHEMBL422872 | AZD-4769 | |
| 1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 315661259 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |